Brief: Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz
21/08/2025 23:04
Aug 21 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O: VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ® Source text: ID:nPn25Pb0La Further company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program